Sign in
Taking people in United StatesNo phase

Opioid Use Disorder and Pain

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Status
Recruiting
People taking part
180 people, planned
Started
4 Feb 2025
Expected to end
Jan 2028
Type of study
Observational, 2 groups
Treatments tested
  • follow up interviews for 12 months to determine opioid use
Record updated
16 June 2026

Who can take part

Age
21 years to 60 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (67)Hide the full registry criteria

Who cannot take part

  • Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded. Individuals who previously worked in metal industry or with metal shavings (due to a risk of any remaining metal particles moving in the eye during the MRI)
  • Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology
  • History of head injury with loss of consciousness (> 30 minutes)
  • Current or past DSM-IV or DSM 5 diagnosis of a major psychiatric disorder (other than opioid and nicotine use disorders) that required hospitalization, or that required daily medications for over 4 weeks. Such medications include antidepressants, anticholinergics, antipsychotics, anxiolytics, lithium, psychotropic drugs not otherwise specified including herbal products, drugs with psychomotor effects or with anxiolytics, stimulant, or antipsychotic properties, any other psychoactive drugs, and sedatives/hypnotics. Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms will be excluded
  • Physically healthy with no major medical illnesses, history of head injury or any neurological illness
  • Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology
  • History of head injury with loss of consciousness (> 30 minutes)
  • Current or past DSM-IV or DSM 5 diagnosis of a major psychiatric disorder (other than opioid and nicotine use disorders) that required hospitalization, or that required daily medications for over 4 weeks. Such medications include antidepressants, anticholinergics, antipsychotics, anxiolytics, lithium, psychotropic drugs not otherwise specified including herbal products, drugs with psychomotor effects or with anxiolytics, stimulant, or antipsychotic properties, any other psychoactive drugs, and sedatives/hypnotics. Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms will be excluded
  • Physically healthy with no major medical illnesses, history of head injury or any neurological illness
  • Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology
  • History of head injury with loss of consciousness (> 30 minutes)
  • Current or past DSM-IV or DSM 5 diagnosis of a major psychiatric disorder (other than opioid and nicotine use disorders) that required hospitalization, or that required daily medications for over 4 weeks. Such medications include antidepressants, anticholinergics, antipsychotics, anxiolytics, lithium, psychotropic drugs not otherwise specified including herbal products, drugs with psychomotor effects or with anxiolytics, stimulant, or antipsychotic properties, any other psychoactive drugs, and sedatives/hypnotics. Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms will be excluded
  • Physically healthy with no major medical illnesses, history of head injury or any neurological illness
  • Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology
  • History of head injury with loss of consciousness (> 30 minutes)
  • Current or past DSM-IV or DSM 5 diagnosis of a major psychiatric disorder (other than opioid and nicotine use disorders) that required hospitalization, or that required daily medications for over 4 weeks. Such medications include antidepressants, anticholinergics, antipsychotics, anxiolytics, lithium, psychotropic drugs not otherwise specified including herbal products, drugs with psychomotor effects or with anxiolytics, stimulant, or antipsychotic properties, any other psychoactive drugs, and sedatives/hypnotics. Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms will be excluded
  • Meet criteria for current or history of any Axis I (except nicotine use) disorder
  • Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology. History of head injury with loss of consciousness (> 30 minutes)
  • Between ages 21-60 years old
  • Between ages 21-60 years old
  • Between ages 21-60 years old
  • Between ages 1821-60 years old
  • Pregnant or lactating women will not be recruited for the study
  • Cannot or are not willing to lie comfortably flat on his/her back for up to 2 hours in the MRI scanner (self-report)
  • Body weight > 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs
  • No pPlans to relocate out of state in the next 12 months (for follow-up purposes)
  • Still experiencing significant withdrawal symptoms; Individuals with regular opioid use; To be eligible for inclusion in the study, an individual must meet all of the following criteria:
  • Able to read and write and provide written informed consent
  • Use non-prescribed opioids on a weekly basis or more
  • No plans to relocate out of state in the next 12 months (for follow-up purposes)
  • Speak English
  • Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded
  • Pregnant or lactating women will not be recruited for the study
  • Cannot or are not willing to lie comfortably flat on his/her back for up to 2 hours in the MRI scanner (self-report)
  • Body weight > 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs; Individuals with regular opioid use; To be eligible for inclusion in the study, an individual must meet all of the following criteria:
  • Able to read and write and provide written informed consent
  • Use non-prescribed opioids on a weekly basis or more
  • No plans to relocate out of state in the next 12 months (for follow-up purposes)
  • Speak English
  • Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded
  • Pregnant or lactating women will not be recruited for the study
  • Cannot or are not willing to lie comfortably flat on his/her back for up to 2 hours in the MRI scanner (self-report)
  • Body weight > 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs; Individuals with regular opioid use; To be eligible for inclusion in the study, an individual must meet all of the following criteria:
  • Able to read and write and provide written informed consent
  • Use non-prescribed opioids on a weekly basis or more
  • No plans to relocate out of state in the next 12 months (for follow-up purposes)
  • Speak English
  • Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded
  • Pregnant or lactating women will not be recruited for the study
  • Cannot or are not willing to lie comfortably flat on his/her back for up to 2 hours in the MRI scanner (self-report)
  • Body weight > 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs; Healthy controls (HC) Inclusion Criteria
  • Able to read and write and provide written informed consent
  • Demographics matching OUD participants
  • Speak English
  • Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded
  • Pregnant or lactating women will not be recruited for the study. 6. Cannot or are not willing to lie comfortably flat on his/her back for up to 2 hours in the MRI scanner (self-report)
  • Body weight > 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs

Other criteria

  • Patients with Opioid Use Disorder (OUD)
  • To be eligible for inclusion in the study, an individual must meet all of the following criteria:
  • Between ages 21-60 years old
  • Able to read and write and provide written informed consent
  • Meet DSM-5 criteria for moderate to severe opioid use disorder; self-reported excessive opioid use prior to study entry and verified by urine toxicology testing; seeking treatment for their OUD
  • Physically healthy with no major medical illnesses, history of head injury or any neurological illness
  • No plans to relocate out of state in the next 12 months (for follow-up purposes)
  • Currently seeking treatment or currently receiving treatment for OUD
  • Speak English
  • Have been enrolled in an inpatient or outpatient treatment program for OUD for at least 4 weeks

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Opioid use disorder

This trial is currently available in United States.

  • Connecticut Mental Health Center, S105New Haven, United StatesContact: Thang M Le, PhDTaking people

About the trial

What the trial wants to find out

The goal of this observational study is to characterize the brain processes of pain avoidance learning dysfunctions in individuals with opioid use disorder (OUD). The main questions it aims to answer are:

Read full original descriptionShow less

Compared with healthy controls, do those with OUD exhibit impaired avoidance learning in response to pain? What are the brain processes that are associated with this avoidance learning dysfunction? Do these brain processes serve to predict future use or relapse?

Researchers will compare those with OUD and healthy controls to determine avoidance learning dysfunction and its relationship with opioid use.

Participants will be performing a learning task inside an fMRI scanner. Those with OUD will also be followed up for a year to determine future opioid use.

The 2 groups in the trial

  • opioid use disorder

    individuals with OUD diagnosis

    Treatment: follow up interviews for 12 months to determine opioid use

  • Healthy controls

    Healthy individuals without substance use disorders

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06800703, who can take part
Record updated
16 June 2026